ES2059931T3 - Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular. - Google Patents

Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular.

Info

Publication number
ES2059931T3
ES2059931T3 ES90115230T ES90115230T ES2059931T3 ES 2059931 T3 ES2059931 T3 ES 2059931T3 ES 90115230 T ES90115230 T ES 90115230T ES 90115230 T ES90115230 T ES 90115230T ES 2059931 T3 ES2059931 T3 ES 2059931T3
Authority
ES
Spain
Prior art keywords
treatment
hypertrophy
vascular
administration
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90115230T
Other languages
English (en)
Inventor
Wolfgang Dr Linz
Bernward Prof Dr Scholkens
Wolfgang Dr Scholz
Gabriele Dr Wiemer
Hansjorg Dr Urbach
Rainer Dr Henning
Volker Dr Teetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6386970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2059931(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2059931T3 publication Critical patent/ES2059931T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

EL INVENTO SE REFIERE A UN COMPUESTO DE FORMULA (I); RESEÑA UN PROCEDIMIENTO PARA TRATAR LA HIPERTROFIA E HIPERPLASIA CARDIALES O VASCULARES MEDIANTE LA APLICACION DE INHIBIDORES DE ENZIMAS CONVERTIDORAS DE ANGIOTENSINAS Y DESCRIBE INHIBIDORES DE ENZIMA CONVERTIDORES DE ANGIOTENSINAS Y MEDIOS CONTENIENDO INHIBIDORES QUE SE UTILIZA PARA EL TRATAMIENTO DE LA HIPERTROFIA E HIPERPLASIA CARDIALES O VASCULARES. SIENDO: R, R1, R2 Y R3 IGUALES O DIFERENTES HIDROGENO O UN RESTO ORGANICO; R4 Y R5 SISTEMA ANULAR MONO, BI O TRICICLO; Y N 1 O 2.
ES90115230T 1989-08-11 1990-08-08 Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular. Expired - Lifetime ES2059931T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3926606A DE3926606A1 (de) 1989-08-11 1989-08-11 Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie

Publications (1)

Publication Number Publication Date
ES2059931T3 true ES2059931T3 (es) 1994-11-16

Family

ID=6386970

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90115230T Expired - Lifetime ES2059931T3 (es) 1989-08-11 1990-08-08 Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular.

Country Status (22)

Country Link
US (1) US5231083A (es)
EP (1) EP0417473B1 (es)
JP (1) JP3452199B2 (es)
KR (1) KR0185969B1 (es)
AT (1) ATE94409T1 (es)
AU (1) AU631914B2 (es)
CA (1) CA2023089C (es)
CS (1) CS277644B6 (es)
DD (1) DD297063A5 (es)
DE (2) DE3926606A1 (es)
DK (1) DK0417473T3 (es)
ES (1) ES2059931T3 (es)
FI (1) FI903936A0 (es)
HU (1) HU205008B (es)
IE (1) IE64604B1 (es)
IL (1) IL95327A (es)
NO (1) NO306979B1 (es)
NZ (1) NZ234836A (es)
PH (1) PH30831A (es)
PL (1) PL286442A1 (es)
PT (1) PT94957B (es)
ZA (1) ZA906327B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE157871T1 (de) 1994-05-19 1997-09-15 Mitsubishi Chem Corp Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
SG68529A1 (en) * 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CN101098679A (zh) * 2004-11-05 2008-01-02 国王医药研究与发展有限公司 稳定的雷米普利组合物及其制备方法
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
SG11201608943VA (en) 2014-04-30 2016-11-29 Univ Columbia Substituted 4-phenylpiperidines, their preparaiton and use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4381297A (en) * 1981-05-04 1983-04-26 E. R. Squibb & Sons, Inc. Substituted carbonyl phosphinyl-alkanoyl compounds
US4602002A (en) * 1983-02-07 1986-07-22 Merck & Co., Inc. N-carboxymethyl substituted lysyl and α-(ε-aminoalkyl) glycyl amino acid antihypertensive agents
US4548941A (en) * 1984-07-30 1985-10-22 Merck & Co., Inc. 1,5-Methano-1H-4-benzazonine dicarboxylates, process for preparing and use as calcium blockers
US4587253A (en) * 1984-07-30 1986-05-06 Merck & Co., Inc. Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4599341A (en) * 1984-10-01 1986-07-08 Merck & Co., Inc. Substituted and bridged pyridines useful as calcium channel blockers
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
DE3705220A1 (de) * 1987-02-19 1988-09-01 Boehringer Ingelheim Kg Mittel zur behandlung von coronarerkrankungen oder organischem hirnsyndrom
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors

Also Published As

Publication number Publication date
DE3926606A1 (de) 1991-02-14
PT94957A (pt) 1991-05-22
CS277644B6 (en) 1993-03-17
PL286442A1 (en) 1992-03-09
HU205008B (en) 1992-03-30
EP0417473A1 (de) 1991-03-20
KR910004189A (ko) 1991-03-28
NO903532D0 (no) 1990-08-10
PT94957B (pt) 1997-05-28
IE64604B1 (en) 1995-08-23
DK0417473T3 (da) 1993-12-13
IE902910A1 (en) 1991-02-27
EP0417473B1 (de) 1993-09-15
NZ234836A (en) 1997-05-26
HU904966D0 (en) 1991-01-28
DE59002721D1 (de) 1993-10-21
NO306979B1 (no) 2000-01-24
PH30831A (en) 1997-10-17
NO903532L (no) 1991-02-12
CS395890A3 (en) 1992-08-12
CA2023089C (en) 2003-01-14
ZA906327B (en) 1991-05-29
ATE94409T1 (de) 1993-10-15
IL95327A0 (en) 1991-06-30
CA2023089A1 (en) 1991-02-12
AU6092090A (en) 1991-02-14
US5231083A (en) 1993-07-27
AU631914B2 (en) 1992-12-10
FI903936A0 (fi) 1990-08-09
IL95327A (en) 1995-10-31
JPH0383957A (ja) 1991-04-09
JP3452199B2 (ja) 2003-09-29
HUT54504A (en) 1991-03-28
DD297063A5 (de) 1992-01-02
KR0185969B1 (ko) 1999-05-01

Similar Documents

Publication Publication Date Title
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
ES2059931T3 (es) Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular.
ES2189330T3 (es) Derivados heterociclicos n6 de la adenosina sustituidos.
UY24244A1 (es) Derivados bicíclicos y policíclicos de isotiazolona
SG43768A1 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative dieases
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
ES2123149T3 (es) Derivados de perhidroisoindol como antagonistas de la substancia p.
AR000929A1 (es) Compuestos herbicidas de bencisoxazol y bencisotiazol substituido, composicion que los comprende y metodos para controlar con los mismos especiesde plantas indeseables.
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
ES2059301T3 (es) Utilizacion de inhibidores de la enzima convertidora de angiotensina para el tratamiento de la aterosclerosis, trombosis y de la enfermedad vascular periferica.
PE25998A1 (es) DERIVADOS DE OCTAHIDRO-PIRROLO(1,2-a)-PIRAZINA 2,7-SUSTITUIDOS
CO4700463A1 (es) Compuestos sustituidos de dihidroimidazo [2,1-b] tiazol y dihidro-5h-tiazol(3,2-a)pirimidina, procedimientos para su preparacion
ES2104174T3 (es) Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos.
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.
PE86698A1 (es) Derivados de indolina
EA199900684A1 (ru) Производные иминоазаантрациклинона для лечения амилоидоза
ES2040750T3 (es) Un procedimiento para la preparacion de un derivado de isoquinolinol.
ES2118818T3 (es) Tiazolin-2-onas aminoalquil-substituidas, su obtencion y empleo.
ES2147316T3 (es) 1-cicloalqueniltetrazolinonas.
ATE96774T1 (de) Hydroxyphenethylamin-derivat und dessen salze, verfahren zur herstellung, medizinische verwendung und verwendung als spezifisches pharmakologisches werkzeug.
ATE85604T1 (de) Verfahren zur herstellung von 4-bromanilinhydrobromiden.
UY24547A1 (es) Procedimiento para preparar derivados de quinolina
ES2032246B1 (es) Procedimiento para la preparacion de una formulacion plaguicida y acaricida solida.
AR014135A1 (es) Profarmacos de lobucavir y metodos de uso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 417473

Country of ref document: ES